Marjolaine Destremau, Hélène Chaussade, Victor Hemar, Mathilde Beguet, Pantxika Bellecave, Elodie Blanchard, Amaury Barret, Gaelle Laboure, Claire Vasco-Moynet, Flore Lacassin, Eloïse Morisse, Claire Aguilar, Xavier Lafarge, Marie-Edith Lafon, Fabrice Bonnet, Nahéma Issa, Fabrice Camou
This study aims to assess the safety, virological, and clinical outcomes of convalescent plasma transfusion (CPT) in immunocompromised patients hospitalized for coronavirus disease 2019 (COVID-19). We conducted a retrospective multicenter cohort study that included all immunosuppressed patients with COVID-19 and RNAemia from May 2020 to March 2023 treated with CPT. We included 81 patients with hematological malignancies (HM), transplants, or autoimmune diseases (69% treated with anti-CD20). Sixty patients (74%) were vaccinated, and 14 had pre-CPT serology >264 BAU/mL...
April 2024: Journal of Medical Virology